Viatris and Biocon mull pooling their biosimilars right into a $10B standalone firm — report – Endpoints Information
Viatris (Mylan/Pfizer’s Upjohn) and India’s Biocon Biologics are reportedly pondering whether or not to further entwine their biosimilar businesses into…